1H-pyrazolo[3,4-b]pyridine-4-thiol | 49834-64-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: 1H-pyrazolo[3,4-b]pyridine-4-thiol
• 英文别名: 1,7-dihydro-pyrazolo[3,4-b]pyridine-4-thione；1,7-dihydropyrazolo[3,4-b]pyridine-4-thione
• CAS: 49834-64-2
• 化学式: C₆H₅N₃S
• 分子量: 151.192
• InChiKey: UOVFYWKXSUTFHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  42.6
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• ARYL AND HETEROARYL SUBSTITUTED INDOLE COMPOUNDS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20210087174A1

  公开（公告）日：2021-03-25

  Disclosed are compounds of Formula (I) or salts thereof, wherein A, G, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
• PROTEIN TYROSINE PHOSPHATASE INHIBITORS
  申请人：Array BioPharma Inc.

  公开号：US20210380582A1

  公开（公告）日：2021-12-09

  Compounds of Formula Ia or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula Ia or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed
• [EN] PROTEIN TYROSINE PHOSPHATASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTÉINE TYROSINE PHOSPHATASE
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2020081848A1

  公开（公告）日：2020-04-23

  Compounds of Formula la or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases in the view of their ability to inhibit SHP2. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.